Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Brazilian (BOVESPA) Healthcare Sector Analysis

UpdatedJul 15, 2026
DataAggregated Company Financials
Companies16
  • 7D4.7%
  • 3M-7.5%
  • 1Y-0.1%
  • YTD-3.0%

In the last week, the Healthcare industry is up 1.9%, with Rede D'Or São Luiz up 2.1%. Meanwhile, Oncoclínicas do Brasil Serviços Médicos actually underperformed within the industry, shrinking 32% in the last week. Despite this gain, the industry's performance has been flat over the past year. Looking forward, earnings are forecast to grow by 29% annually.

Sector Valuation and Performance

Has the Brazilian Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Jul 2026R$166.1bR$155.3bR$2.9b11.4x57.5x1.1x
Fri, 12 Jun 2026R$155.3bR$155.3bR$2.9b13.1x53.8x1x
Sun, 10 May 2026R$138.8bR$156.3bR$3.3b12.2x42.5x0.9x
Tue, 07 Apr 2026R$138.5bR$154.2bR$3.7b12.5x37.8x0.9x
Thu, 05 Mar 2026R$137.1bR$153.7bR$2.1b14.1x65.5x0.9x
Sat, 31 Jan 2026R$149.6bR$152.1bR$1.8b12.9x81x1x
Mon, 29 Dec 2025R$145.9bR$152.1bR$1.8b12x79.1x1x
Wed, 26 Nov 2025R$152.9bR$152.1bR$1.9b12.3x82.2x1x
Fri, 24 Oct 2025R$150.6bR$149.9bR$2.5b11.5x60.3x1x
Sun, 21 Sep 2025R$156.2bR$149.9bR$2.5b12.2x62.6x1x
Tue, 19 Aug 2025R$146.6bR$144.3bR$2.5b12.2x58.6x1x
Thu, 17 Jul 2025R$135.3bR$149.5bR$2.0b11.1x66.4x0.9x
Sat, 14 Jun 2025R$140.9bR$149.5bR$2.0b11.1x69.1x0.9x
Mon, 12 May 2025R$133.3bR$149.0bR$2.2b10.7x61.3x0.9x
Wed, 09 Apr 2025R$116.5bR$150.7bR$3.6b10.1x32.6x0.8x
Fri, 07 Mar 2025R$115.1bR$146.8bR$4.7b10.8x24.5x0.8x
Sun, 02 Feb 2025R$117.6bR$146.7bR$4.7b11.5x25.2x0.8x
Tue, 31 Dec 2024R$109.7bR$146.7bR$4.7b11.3x23.5x0.7x
Thu, 28 Nov 2024R$130.0bR$148.2bR$5.3b12.3x24.7x0.9x
Sat, 26 Oct 2024R$142.8bR$144.9bR$4.4b11.2x32.5x1x
Mon, 23 Sep 2024R$154.0bR$144.9bR$4.4b11.2x35x1.1x
Wed, 21 Aug 2024R$160.5bR$144.9bR$4.4b12x36.5x1.1x
Fri, 19 Jul 2024R$142.8bR$143.3bR$4.2b11.5x34.3x1x
Sun, 16 Jun 2024R$137.1bR$142.9bR$4.2b11.3x32.8x1x
Tue, 14 May 2024R$150.4bR$142.3bR$3.8b12.2x39.5x1.1x
Thu, 11 Apr 2024R$139.2bR$140.0bR$3.2b12.2x43.9x1x
Sat, 09 Mar 2024R$145.1bR$133.0bR$2.7b14.6x53x1.1x
Mon, 05 Feb 2024R$150.7bR$135.0bR$2.9b16.7x52.3x1.1x
Wed, 03 Jan 2024R$164.2bR$135.0bR$2.9b20.5x56.9x1.2x
Fri, 01 Dec 2023R$158.7bR$135.0bR$2.9b20x55x1.2x
Sun, 29 Oct 2023R$147.0bR$126.2bR$2.8b17.9x52.9x1.2x
Tue, 26 Sep 2023R$163.0bR$126.1bR$2.7b19.5x59.3x1.3x
Thu, 24 Aug 2023R$179.6bR$126.1bR$2.7b20.6x65.4x1.4x
Sat, 22 Jul 2023R$189.6bR$116.7bR$2.8b16.7x67.3x1.6x
Price to Earnings Ratio

67.3x


Total Market Cap: R$189.6bTotal Earnings: R$2.8bTotal Revenue: R$116.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Brazilian Healthcare Sector Price to Earnings3Y Average 51x202420252026
Current Industry PE
  • Investors are optimistic on the Brazilian Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 56.7x which is higher than its 3-year average PE of 51.0x.
  • The industry is trading close to its 3-year average PS ratio of 1.0x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have grown 10.0% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the Brazilian Healthcare sector?

BR Market3.37%
Healthcare4.65%
Healthcare Services4.85%
Pharma4.16%
Medical Equipment0%0
Biotech-0.92%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 117x.
    • Analysts are expecting annual earnings growth of 30.3%, which is higher than its past year's earnings growth of 0.5% per year.
  • Investors are most pessimistic about the Pharma industry, which is trading below its 3-year average of 13.3x.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 30% over the next 5 years.
  • This is better than its past earnings growth rate of 0.5% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 15% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
RDOR3 Rede D'Or São LuizR$36.055.8%
+R$4.3b		7.3%PE17.2x
SAUD3 BradsaúdeR$15.352.3%
+R$1.0b		34.6%PE79.4x
HYPE3 HyperaR$21.034.5%
+R$640.2m		-24.8%PE8.8x
HAPV3 Hapvida Participações e InvestimentosR$11.1912.3%
+R$584.3m		-66.6%PS0.2x
FLRY3 FleuryR$16.416.5%
+R$543.6m		28.0%PE14.1x

Latest News

RDOR3
R$36.05
Rede D'Or São Luiz
7D
5.8%
1Y
7.3%
Narrative Update • Jul 14

RDOR3: Sustainability Index Exit Will Shape Future Risk And Return Profile

Analysts have revised their valuation outlook for Rede D'Or São Luiz. The fair value estimate has moved from R$36.70 to about R$38.64 as they incorporate updated assumptions on the discount rate, revenue growth, profit margin and future P/E.
BLAU3
R$10.29
Blau Farmacêutica
7D
-1.0%
1Y
3.6%
MATD3
R$4.87
Hospital Mater Dei
7D
5.9%
1Y
5.9%
Narrative Update • Jul 10

nan

Analysts have revised their price target for Hospital Mater Dei higher to reflect updated fair value assumptions of R$6.30, along with refreshed views on the discount rate, revenue growth, profit margin, and future P/E expectations. What’s in the News for Hospital Mater Dei No recent news stories or key developments for Hospital Mater Dei were provided in the available sources.
DASA3
R$2.66
Diagnósticos da América
7D
8.1%
1Y
111.1%
Narrative Update • Jul 10

DASA3: Index Inclusion Will Support Re Rated P/E Multiple

Analysts have lifted their price target for Diagnósticos da América to R$4.16 from R$2.91, citing updated assumptions for revenue growth and profit margins, as well as a higher assumed future P/E multiple. What's in the News Diagnósticos da América S.A. was added to the Brazil Small Cap Index, according to a key index constituent update.
SAUD3
R$15.35
Bradsaúde
7D
2.3%
1Y
34.6%
Narrative Update • Jul 08

SAUD3: Index Inclusion Will Support Higher Future Earnings Multiple

Analysts have revised their price target on Bradsaúde from R$18.00 to R$19.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. What’s in the News for Bradsaúde Bradsaúde scheduled a board meeting for May 4, 2026, at 12:00 Coordinated Universal Time to consider approval of Odontoprev S.A.'s first quarter 2026 results.
HAPV3
R$11.19
Hapvida Participações e Investimentos
7D
12.3%
1Y
-66.6%
Narrative Update • Jul 03

HAPV3: Margin Recovery And Execution Risks Will Shape Future Share Upside

The updated fair value estimate for Hapvida Participações e Investimentos rises from R$7.00 to R$10.00, as analysts take into account a higher discount rate, slightly lower revenue growth and a modestly lower future P/E, while still looking for margin recovery following recent research that includes both an upgrade with a R$19 price target and a downgrade from other firms. Analyst Commentary Recent research on Hapvida Participações e Investimentos highlights a split in views, with some firms turning more constructive on the stock while others stay cautious.
QUAL3
R$1.68
Qualicorp Consultoria e Corretora de Seguros
7D
5.7%
1Y
-4.5%
ONCO3
R$0.96
Oncoclínicas do Brasil Serviços Médicos
7D
-9.4%
1Y
-81.9%
HYPE3
R$21.03
Hypera
7D
4.5%
1Y
-24.8%
Narrative Update • Jun 26

HYPE3: Stricter Working Capital And Margin Tailwinds Will Support Future Upside

Hypera's analyst fair value estimate has shifted from R$22.00 to R$25.00 as analysts factor in stricter working capital conditions, gross margin tailwinds, and a higher assumed future P/E multiple supported by the recent upgrade in Street research. What's in the News for Hypera Board meeting scheduled for Jun 23, 2026, at 17:00 UTC to consider, in accordance with the company bylaws, the distribution of interest on equity of R$0.26304 per ordinary share and any other matters on the agenda.
FLRY3
R$16.41
Fleury
7D
6.5%
1Y
28.0%
Narrative Update • Jun 19

FLRY3: Fair View Will Reflect Updated Assumptions And Support Bullish Outlook

Analysts have trimmed their R$ fair value estimate for Fleury slightly to about R$17.35, from roughly R$17.45, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News for Fleury No recent Fleury company news items were identified in the provided sources.
VVEO3
R$0.60
CM Hospitalar S/A
7D
-1.6%
1Y
-48.3%
BIOM3
R$6.19
Biomm
7D
-0.8%
1Y
-18.6%
Analysis Article • May 22

We Think That There Are Issues Underlying Biomm's (BVMF:BIOM3) Earnings

Investors were disappointed with Biomm S.A.'s ( BVMF:BIOM3 ) earnings, despite the strong profit numbers. We think that...